Supriya Lifescience Secures USFDA Green Light for Lote Facility

Supriya Lifescience, an API manufacturer, announced that it has received an Establishment Inspection Report from the US FDA for its Lote facility. The facility received a Voluntary Action Indicated classification, reflective of robust quality systems.

The inspection, conducted in early February 2026, concluded with a Form 483 noting only one minor observation. This outcome enables Supriya Lifescience to maintain its API supplies to major markets, such as the US, Europe, and Japan without disruptions.

Executive Chairman Dr. Satish Wagh emphasized that this success mirrors the company's steadfast focus on regulatory excellence, positioning Supriya Lifescience as a key partner for pharmaceutical firms globally.